Evidence map›Paper›PMID 29906480›Full record

ArticleUrology2018

The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.

Lauren P Wallner, Julia R DiBello, Bonnie H Li, Stephen K Van Den Eeden, Sheila Weinmann, Debra P Ritzwoller, Jill E Abell, Ralph D'Agostino, Ronald K Loo, David S Aaronson and 2 more

Open access · greenAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Nutrients · 2023
    Article
  3. Article
  4. Article
  5. Round up.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Lauren P WallnerDepartment of Medicine and Epidemiology, University of Michigan, Ann Arbor, USA, MI; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, USA, CA. Electronic address: lwallner@med.umich.edu.
Julia R DiBelloReal World Evidence & Epidemiology, GlaxoSmithKline, Harrisburg, USA, PA.
Bonnie H LiDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, USA, CA.
Stephen K Van Den EedenDivision of Research, Kaiser Permanente Northern California, Oakland, USA, CA.
Sheila WeinmannCenter for Health Research, Kaiser Permanente Northwest, Portland, USA, OR.
Debra P RitzwollerInstitute for Health Research, Kaiser Permanente Colorado, Denver, USA, CO.
Jill E AbellReal World Evidence, Janssen, Horsham, USA, PA.
Ralph D'AgostinoDepartment of Biostatistical Science, Wake Forest University, Winston-Salem, USA NC.
Ronald K LooDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, USA, CA.
David S AaronsonDivision of Research, Kaiser Permanente Northern California, Oakland, USA, CA.
Ralph I HorwitzInstitute for Transformative Medicine, Temple University and Visiting Scholar, Institute of Medicine, Philadelphia, USA, PA.
Steven J JacobsenDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, USA, CA.
Kaiser Permanente · USGlaxoSmithKline (United States) · USJanssen (United States) · USKaiser Permanente Center for Health Research · USTemple University · USWake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
NCI NIH HHS P30 CA012197
6 · The paper itself

Abstract

objectiveTo compare the risk of mortality among men treated for benign prostatic hyperplasia (BPH) with 5 alpha-reductase inhibitors (5ARI) to those treated with alpha-blockers (AB) in community practice settings.

methodsWe employed a retrospective matched cohort study in 4 regions of an integrated healthcare system. Men aged 50 years and older who initiated pharmaceutical treatment for BPH and/or lower urinary tract symptoms between 1992 and 2008 and had at least 3 consecutive prescriptions that were eligible and followed through 2010 (N = 174,895). Adjusted hazard ratios were used to estimate the risk of mortality due to all-causes associated with 5ARI use (with or without concomitant ABs) as compared to AB use.

resultsIn this large and diverse sample with 543,523 person-years of follow-up, 35,266 men died during the study period, 18.9% of the 5ARI users and 20.4% of the AB users. After adjustment for age, medication initiation year, race, region, prior AB history, Charlson score, and comorbidities, 5ARI use was not associated with an increased risk of mortality when compared to AB use (Adjusted hazard ratios: 0.64, 95% confidence interval: 0.62, 0.66).

conclusionAmong men receiving medications for BPH in community practice settings, 5ARI use was not associated with an increased risk of mortality when compared to AB use. These data provide reassurance about the safety of using 5ARIs in general practice to manage BPH and/or lower urinary tract symptoms.

Indexed as

5-alpha Reductase InhibitorsAdrenergic alpha-AntagonistsAgedCause of DeathCohort StudiesHumansMaleMiddle AgedProstatic HyperplasiaRetrospective StudiesRisk Assessment5-alpha Reductase InhibitorsAdrenergic alpha-Antagonists5 Alpha-reductase inhibitorsAlpha-blockersBenign prostatic hyperplasiaLower urinary tract symptomsMortality

Identifiers

PMID29906480
PMCPMC8080272
OpenAlexW2808355002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.